Denver Nephrologists, P.C.   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Denver CO United States

Organization Overview

First Clinical Trial
2009
NCT00785629
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Denver Nephrologists, PC | Geoffrey Block

Active Ingredients

Drugs in Phase 3 Trials (3)

epoetin (Epogen) (1 trial)

ferric citrate (auryxia) (1 trial)

roxadustat (1 trial)

Drugs in Phase 1 Trials (1)

gcs-100 (1 trial)

Drugs in Other Trials (4)

agalsidase alfa (Replagal) (1 trial)

calcium (1 trial)

lanthanum (2 trials)

sevelamer (renagel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Hyperphosphatemia (Phase 3)

Kidney Diseases (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 8